- Home
- EQ vs ENLV Comparison
EQ vs ENLV Comparison
Compare EQ & ENLV Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | EQ | ENLV |
|---|---|---|
| Founded | 2017 | 2005 |
| Country | United States | Israel |
| Employees | 14 | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 140.1M | 149.0M |
| IPO Year | 2018 | 2014 |
Fundamental Metrics
Financial Performance| Metric | EQ | ENLV |
|---|---|---|
| Price | $2.24 | $1.11 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 3 | 2 |
| Target Price | $8.00 | ★ $20.00 |
| AVG Volume (30 Days) | ★ 423.3K | 268.5K |
| Earning Date | 05-25-2026 | 05-29-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $41,095,000.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $0.76 | $0.43 |
| 52 Week High | $3.54 | $7.64 |
Technical Indicators
Market Signals| Indicator | EQ | ENLV |
|---|---|---|
| Relative Strength Index (RSI) | 44.14 | 31.73 |
| Support Level | $2.15 | $1.00 |
| Resistance Level | $2.58 | $1.26 |
| Average True Range (ATR) | 0.16 | 0.16 |
| MACD | 0.01 | -0.00 |
| Stochastic Oscillator | 10.00 | 4.41 |
Price Performance
Historical ComparisonAbout EQ Equillium Inc.
Equillium Inc is a biotechnology innovator developing novel therapies to treat severe autoimmune and inflammatory disorders with the mission to develop life-changing therapeutics for patients. It primary goal is to advance EQ504, a novel aryl hydrocarbon receptor, or AhR, modulator, into and through clinical development. The Company operates through a single operating and reportable segment focused on the business of developing novel therapies to treat severe autoimmune and inflammatory disorders, with the mission to develop life-changing therapeutics for patients. The Company manages all business activities on a consolidated basis.
About ENLV Enlivex Therapeutics Ltd.
Enlivex Ltd is a clinical stage macrophage reprogramming immunotherapy company currently focused on the late-stage clinical development of Allocetra, a novel therapy designed to treat the joint disease osteoarthritis. Additionally, it has developed a treasury using the RAIN protocol, which currently serves as the primary treasury reserve asset of the company.